Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
DOI:
https://doi.org/10.14739/2310-1237.2022.2.259260Keywords:
sST2, cardiovascular events, multiple myeloma, survival, prognosisAbstract
Aim. We aimed to evaluate the prognostic value of circulating sST2 for cumulative cardiovascular events in patients with multiple myeloma.
Materials and methods. Ninety seven patients with complete or partial remission of multiple myeloma were enrolled in the study. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of sST2 was used.
Results. During observation period progression of multiple myeloma was proved in 25 patients, 5 persons were excluded for poor follow-up. 67 patients were included into statistical analysis. Thirty six cumulative clinical events occurred in 18 patients (26.9 %) within the follow-up, with their distribution being as follows: 2 deaths due to cardiovascular causes, 16 heart arrhythmias, 3 cardiac ischemic events, 1 stroke, 4 episodes of chronic heart failures and 10 hospital admissions due to cardiovascular events. 2 deaths were not related to cardiovascular pathology. Medians of levels of sST2 in free-events patients and patients with cardiovascular events were 24.17 ng/ml (95 % confidence interval (CI) = 12.87–27.48 ng/ml) and 47.57 ng/ml (95 % CI = 21.36–68.79 ng/ml) (Р < 0.01) respectively. In multivariate logistic regression analysis sST2 independently predicted cardiovascular events (odds ratio (OR) = 1.112; 95 % CI = 1.081–1.154; Р = 0.010) within 1 year of observation period.
Conclusions. Among patients with confirmed multiple myeloma at remission increased level of circulating sST2 associates with increased cumulative cardiovascular events during 1 year.
References
Bazyka, D. A., Gudzenko, N. A., Dyagil, I. S., Babkina, N. G., Chumak, V. V., Bakhanova, E. V., Paramonov, V. V., & Romanenko, A. Y. (2013). Multiple myeloma among Chornobyl accident clean-up workers - state and perspectives of analytical study. Problemy radiatsiinoi medytsyny ta radiobiolohii, (18), 169-172.
Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC cancer, 14, 496. https://doi.org/10.1186/1471-2407-14-496
De Stefano, V., Za, T., & Rossi, E. (2014). Venous thromboembolism in multiple myeloma. Seminars in thrombosis and hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793
Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M. A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M., & Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 32(9), 1883-1898. https://doi.org/10.1038/s41375-018-0209-7
Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature reviews. Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65
Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. H. (2018). Cardiovascular adverse events in multiple myeloma patients. Journal of thoracic disease, 10(35), S4296-S4305. https://doi.org/10.21037/jtd.2018.09.87
Samura, B. B. (2012). Serdechno-sosudistye oslozhneniya polikhimioterapii onkogematologicheskikh zabolevanii: sovremennye podkhody k diagnostike [Cardiovascular complications of polychemotherapy of oncohematological diseases: modern approaches to diagnostics]. Zaporozhye Medical Journal, (6), 31-37. [in Russian].
Araujo-Gutierrez, R., Chitturi, K. R., Xu, J., Wang, Y., Kinder, E., Senapati, A., Chebrolu, L. B., Kassi, M., & Trachtenberg, B. H. (2021). Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardio-oncology, 7(1), 4. https://doi.org/10.1186/s40959-021-00090-2
Yu, A. F., & Ky, B. (2016). Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart (British Cardiac Society), 102(6), 425-430. https://doi.org/10.1136/heartjnl-2015-307894
Alexandre, J., Cautela, J., Ederhy, S., Damaj, G. L., Salem, J. E., Barlesi, F., Farnault, L., Charbonnier, A., Mirabel, M., Champiat, S., Cohen-Solal, A., Cohen, A., Dolladille, C., & Thuny, F. (2020). Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. Journal of the American Heart Association, 9(18), e018403. https://doi.org/10.1161/JAHA.120.018403
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., von Haehling, S., Belenkov, Y., … Lyon, A. R. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European journal of heart failure, 22(11), 1966-1983. https://doi.org/10.1002/ejhf.2017
Ananthan, K., & Lyon, A. R. (2020). The Role of Biomarkers in Cardio-Oncology. Journal of cardiovascular translational research, 13(3), 431-450. https://doi.org/10.1007/s12265-020-10042-3
Hinrichs, L., Mrotzek, S. M., Mincu, R. I., Pohl, J., Röll, A., Michel, L., Mahabadi, A. A., Al-Rashid, F., Totzeck, M., & Rassaf, T. (2020). Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry. Frontiers in pharmacology, 11, 740. https://doi.org/10.3389/fphar.2020.00740
Tan, L. L., & Lyon, A. R. (2018). Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current treatment options in cardiovascular medicine, 20(7), 55. https://doi.org/10.1007/s11936-018-0641-z
Bracun, V., Aboumsallem, J. P., van der Meer, P., & de Boer, R. A. (2020). Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Current oncology reports, 22(7), 67. https://doi.org/10.1007/s11912-020-00930-x
Tseluyko, V. I., & Radchenko, O. V. (2018). Serdechno-sosudistye zabolevaniya u onkologicheskikh bol'nykh [Cardiovascular disease in oncological patients]. Liky Ukrainy, (3), 7-20. [in Russian]. https://doi.org/10.37987/1997-9894.2018.3(219)
Monsuez, J. J., Charniot, J. C., Vignat, N., & Artigou, J. Y. (2010). Cardiac side-effects of cancer chemotherapy. International journal of cardiology, 144(1), 3-15. https://doi.org/10.1016/j.ijcard.2010.03.003
Vianello, E., Dozio, E., Tacchini, L., Frati, L., & Corsi Romanelli, M. M. (2019). ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology, 116, 105619. https://doi.org/10.1016/j.biocel.2019.105619
Huang, G., Zhai, J., Huang, X., & Zheng, D. (2018). Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine, 97(38), e12447. https://doi.org/10.1097/MD.0000000000012447
Aula, H., Skyttä, T., Tuohinen, S., Luukkaala, T., Hämäläinen, M., Virtanen, V., Raatikainen, P., Moilanen, E., & Kellokumpu-Lehtinen, P. L. (2020). ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast, 49, 183-186. https://doi.org/10.1016/j.breast.2019.12.001
Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4
Mor-Avi, V., & Lang, R. M. (2012). Transthoracic Three-Dimensional Echocardiography. In Advanced Approaches in Echocardiography (pp. 1-20). Elsevier. https://doi.org/10.1016/b978-1-4377-2697-8.00001-8
Ministry of Health of Ukraine. (2015, November 2). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy: mnozhynna miieloma [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Multiple myeloma" (No. 710)]. [in Ukrainian]. https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_710_MM/2015_710_YKPMD_MM.pdf
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
